公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2017 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial | Lu J.; Lee J.H.; SHANG-YI HUANG ; Qiu L.; Lee J.-J.; Liu T.; Yoon S.-S.; Kim K.; Shen Z.X.; Eom H.S.; Chen W.M.; Min C.K.; Kim H.J.; Lee J.O.; Kwak J.Y.; Yiu W.; Chen G.; Ervin-Haynes A.; Hulin C.; Facon T. | British Journal of Haematology | 10 | 11 | |
2018 | Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: Subgroup analyses of the phase 3 POLLUX study | Suzuki K.; Dimopoulos M.A.; Takezako N.; Okamoto S.; Shinagawa A.; Matsumoto M.; Kosugi H.; Yoon S.-S.; SHANG-YI HUANG ; Qin X.; Qi M.; Iida S. | Blood Cancer Journal | 21 | 23 | |
2020 | Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis | SHANG-YI HUANG ; Yoon S.-S.; Shimizu K.; Chng W.J.; Chang C.-S.; Wong R.S.-M.; Gao S.; Wang Y.; Gordon S.W.; Glennane A.; Min C.-K. | Advances in Therapy | 11 | 8 | |
2019 | Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial | Smith C.C.; Levis M.J.; Perl A.E.; Martinelli G.; Neubauer A.; Berman E.; Montesinos P.; Baer M.R.; Larson R.A.; WEN-CHIEN CHOU ; Yokoyama H.; Recher C.; Yoon S.-S.; Hill J.E.; Rosales M.; Bahceci E. | Blood | 6 | 14 | |
2019 | Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML | Perl A.E.; Martinelli G.; Cortes J.E.; Neubauer A.; Berman E.; Paolini S.; Montesinos P.; Baer M.R.; Larson R.A.; Ustun C.; Fabbiano F.; Erba H.P.; Di Stasi A.; Stuart R.; Olin R.; Kasner M.; Ciceri F.; WEN-CHIEN CHOU ; Podoltsev N.; Recher C.; Yokoyama H.; Hosono N.; Yoon S.-S.; Lee J.-H.; Pardee T.; Fathi A.T.; Liu C.; Hasabou N.; Liu X.; Bahceci E.; Levis M.J. | New England Journal of Medicine | 727 | 689 | |
2019 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network | Soekojo C.Y.; Kim K.; SHANG-YI HUANG ; Chim C.-S.; Takezako N.; Asaoku H.; Kimura H.; Kosugi H.; Sakamoto J.; Gopalakrishnan S.K.; Nagarajan C.; Wei Y.; Moorakonda R.; Lee S.L.; Lee J.J.; Yoon S.-S.; Kim J.S.; Min C.K.; Lee J.-H.; Durie B.; Chng W.J. | Blood Cancer Journal | 12 | 7 |